Investors looking for stocks that can make dramatic gains in a short time frame might want to turn their attention to the biopharmaceutical industry. Shares of Viking Therapeutics (NASDAQ: VKTX) have already risen more than four-fold this year.

Despite Viking's rapid ascent Oppenheimer analyst, Jay Olson thinks it can climb much higher over the next 12 months. Olson recently raised his price target for Viking Therapeutics to $138 from $116 and kept an outperform rating on the stock.

Oppenheimer's raised price target is a response to positive clinical trial results for an experimental weight-management therapy Viking Therapeutics is developing named VK2735.

Continue reading

Source Fool.com